Bristol Myers Squibb

In terms of profits and interest gained from stock investment, Bristol Myers Squibb is a more promising stock. The projected continuous growth rate results in a positive stock value of 31.63$, which is far too hopeful. Dividend returns for the year are likewise high and prospective, standing at 1.6452. (Marketwatch, 2017). Many corporations have been subjected to economic sabotage by their home country. Which also affects the performance of the company (Marketwatch, 2017). However, with the challenges in the country economic standards the company is still doing well will away promising a return on investment.

Graph showing the Growth in stock for the company

Financial Ratios

Current ratio= 13.06/8.22 = 1.59

Sales trend = (5.24-5.21)/5.24 = 1.0057

Comparison to the industry ratio= TEVA Pharmaceuticals revenue/entire industry returns =

5.24/98.67 = 0.0531

(Yahoo Finance, 2017)

Economics

Inflation has been affecting different companies in the global economic sector. The company received a brow in the 2007/2008 inflation which affected different countries in the country. However, beyond the blow in the economy from inflation, the company has enough recovered from the lows to the current level.

Latest News

FDA grants

The FDA grants have accelerated a review on the Bristol-Myers. The FDA has made acceptance of the under priorities reviewed for Bristol-Myers Squibb’s in the NYSE market applications which seek to be approved to the Option in treating the patients which are at high peril advanced Melanoma which is a breakthrough Therapies indications (Yahoo Finance, 2017). The news will bring a change in the Stock sale in the NYSE (Yahoo Finance, 2017).

TEVA Pharmaceuticals

D1 = D0 (1 + g)

D1 = 0.09 (1 + 0.0546)

=0.0949

Value of Stock =

= 0.0949/-0.6427= -0.1477$

(Yahoo Finance, 2017)

The two TEVA Pharmaceuticals stock seems not to have promising returns which have been losing with time. The value of the stock is negative showing that the stock could only be bought by put options (Yahoo Finance, 2017). The rate of decreasing is increasing making it a weak investment for the call option. The stock has a promising dividend.

TEVA Growth in Stock Graph

Financial Ratios

Current ratio= 32.95/35.05 = 0.94

Sales trend = (0.65-0.61)/0.65 = 0.0615

Comparison to the industry ratio= Bristol Myers Squibb returns/entire industry returns =

0.65/34.54 = 0.0188 (Yahoo Finance, 2017)

Economics

Inflation has been affecting different companies in the global economic sector. The company received a brow in the 2007/2008 inflation which affected different countries in the country. However, beyond the blow in the economy from inflation, the company has tried enough to recover from the lows to the current level.

Latest News

TEVA Pharmaceuticals have announced that the submissions of the biologics licenses applications in the Fremanezumab to the USA FDA (TEVA Pharmaceutical Industries Ltd, 2017). The act will make it easier to work to have the country develop in financial matters. The company has been losing out in the profits, but with the new deal, the company is assured of good performance in future (TEVA Pharmaceutical Industries Ltd, 2017).

References

TEVA Pharmaceutical Industries Ltd (2017). Latest News. Retrieved from:

http://www.tevapharm.com/news/. Accessed on 20th Oct 2017.

Yahoo Finance (2017). TEVA. Retrieved from:

https://finance.yahoo.com/quote/TEVA?p=TEVA. Accessed on 20th Oct 2017.

Yahoo Finance (2017). BMY. Retrieved from:

https://finance.yahoo.com/quote/BMY?p=BMY. Accessed on 20th Oct 2017.

Marketwatch (2017). TEVA. Retrieved from:

https://www.marketwatch.com/investing/stock/teva. Accessed on 20th Oct 2017.